369 related articles for article (PubMed ID: 28507103)
41. SIRT6 deacetylase activity regulates NAMPT activity and NAD(P)(H) pools in cancer cells.
Sociali G; Grozio A; Caffa I; Schuster S; Becherini P; Damonte P; Sturla L; Fresia C; Passalacqua M; Mazzola F; Raffaelli N; Garten A; Kiess W; Cea M; Nencioni A; Bruzzone S
FASEB J; 2019 Mar; 33(3):3704-3717. PubMed ID: 30514106
[TBL] [Abstract][Full Text] [Related]
42. Structure-Based Design of Potent Nicotinamide Phosphoribosyltransferase Inhibitors with Promising in Vitro and in Vivo Antitumor Activities.
Bai J; Liao C; Liu Y; Qin X; Chen J; Qiu Y; Qin D; Li Z; Tu ZC; Jiang S
J Med Chem; 2016 Jun; 59(12):5766-79. PubMed ID: 27224875
[TBL] [Abstract][Full Text] [Related]
43. Epigenetic Regulation of
Zhang H; Zhang N; Liu Y; Su P; Liang Y; Li Y; Wang X; Chen T; Song X; Sang Y; Duan Y; Zhang J; Wang L; Chen B; Zhao W; Guo H; Liu Z; Hu G; Yang Q
Cancer Res; 2019 Jul; 79(13):3347-3359. PubMed ID: 30940661
[TBL] [Abstract][Full Text] [Related]
44. Identification of potent triazolylpyridine nicotinamide phosphoribosyltransferase (NAMPT) inhibitors bearing a 1,2,3-triazole tail group.
Travelli C; Aprile S; Mattoteia D; Colombo G; Clemente N; Scanziani E; Terrazzino S; Alisi MA; Polenzani L; Grosa G; Genazzani AA; Tron GC; Galli U
Eur J Med Chem; 2019 Nov; 181():111576. PubMed ID: 31400709
[TBL] [Abstract][Full Text] [Related]
45. Nicotinamide phosphoribosyltransferase (Nampt) in carcinogenesis: new clinical opportunities.
Chen H; Wang S; Zhang H; Nice EC; Huang C
Expert Rev Anticancer Ther; 2016 Aug; 16(8):827-38. PubMed ID: 27186719
[TBL] [Abstract][Full Text] [Related]
46. Cardiotoxicity Associated with Nicotinamide Phosphoribosyltransferase Inhibitors in Rodents and in Rat and Human-Derived Cells Lines.
Misner DL; Kauss MA; Singh J; Uppal H; Bruening-Wright A; Liederer BM; Lin T; McCray B; La N; Nguyen T; Sampath D; Dragovich PS; O'Brien T; Zabka TS
Cardiovasc Toxicol; 2017 Jul; 17(3):307-318. PubMed ID: 27783203
[TBL] [Abstract][Full Text] [Related]
47. Nicotinamide phosphoribosyltransferase (Nampt) may serve as the marker for osteoblast differentiation of bone marrow-derived mesenchymal stem cells.
He X; He J; Shi Y; Pi C; Yang Y; Sun Y; Ma C; Lin L; Zhang L; Li Y; Li Y
Exp Cell Res; 2017 Mar; 352(1):45-52. PubMed ID: 28159473
[TBL] [Abstract][Full Text] [Related]
48. Nicotinamide phosphoribosyltransferase regulates cell survival through NAD+ synthesis in cardiac myocytes.
Hsu CP; Oka S; Shao D; Hariharan N; Sadoshima J
Circ Res; 2009 Aug; 105(5):481-91. PubMed ID: 19661458
[TBL] [Abstract][Full Text] [Related]
49. Advances in NAD-Lowering Agents for Cancer Treatment.
Ghanem MS; Monacelli F; Nencioni A
Nutrients; 2021 May; 13(5):. PubMed ID: 34068917
[TBL] [Abstract][Full Text] [Related]
50. Inhibitor of Nicotinamide Phosphoribosyltransferase Sensitizes Glioblastoma Cells to Temozolomide via Activating ROS/JNK Signaling Pathway.
Feng J; Yan PF; Zhao HY; Zhang FC; Zhao WH; Feng M
Biomed Res Int; 2016; 2016():1450843. PubMed ID: 28097126
[TBL] [Abstract][Full Text] [Related]
51. Inhibition of NAMPT sensitizes MOLT4 leukemia cells for etoposide treatment through the SIRT2-p53 pathway.
Grohmann T; Penke M; Petzold-Quinque S; Schuster S; Richter S; Kiess W; Garten A
Leuk Res; 2018 Jun; 69():39-46. PubMed ID: 29653431
[TBL] [Abstract][Full Text] [Related]
52. Dual nicotinamide phosphoribosyltransferase and epidermal growth factor receptor inhibitors for the treatment of cancer.
Zhang W; Zhang K; Yao Y; Liu Y; Ni Y; Liao C; Tu Z; Qiu Y; Wang D; Chen D; Qiang L; Li Z; Jiang S
Eur J Med Chem; 2021 Feb; 211():113022. PubMed ID: 33239261
[TBL] [Abstract][Full Text] [Related]
53. Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) as a therapeutic strategy in cancer.
Sampath D; Zabka TS; Misner DL; O'Brien T; Dragovich PS
Pharmacol Ther; 2015 Jul; 151():16-31. PubMed ID: 25709099
[TBL] [Abstract][Full Text] [Related]
54. SAR and characterization of non-substrate isoindoline urea inhibitors of nicotinamide phosphoribosyltransferase (NAMPT).
Curtin ML; Heyman HR; Clark RF; Sorensen BK; Doherty GA; Hansen TM; Frey RR; Sarris KA; Aguirre AL; Shrestha A; Tu N; Woller K; Pliushchev MA; Sweis RF; Cheng M; Wilsbacher JL; Kovar PJ; Guo J; Cheng D; Longenecker KL; Raich D; Korepanova AV; Soni NB; Algire MA; Richardson PL; Marin VL; Badagnani I; Vasudevan A; Buchanan FG; Maag D; Chiang GG; Tse C; Michaelides MR
Bioorg Med Chem Lett; 2017 Aug; 27(15):3317-3325. PubMed ID: 28610984
[TBL] [Abstract][Full Text] [Related]
55. Nicotinamide phosphoribosyltransferase (NAMPT) inhibitors as therapeutics: rationales, controversies, clinical experience.
Montecucco F; Cea M; Bauer I; Soncini D; Caffa I; Lasigliè D; Nahimana A; Uccelli A; Bruzzone S; Nencioni A
Curr Drug Targets; 2013 Jun; 14(6):637-43. PubMed ID: 23531116
[TBL] [Abstract][Full Text] [Related]
56. The small molecule GMX1778 is a potent inhibitor of NAD+ biosynthesis: strategy for enhanced therapy in nicotinic acid phosphoribosyltransferase 1-deficient tumors.
Watson M; Roulston A; Bélec L; Billot X; Marcellus R; Bédard D; Bernier C; Branchaud S; Chan H; Dairi K; Gilbert K; Goulet D; Gratton MO; Isakau H; Jang A; Khadir A; Koch E; Lavoie M; Lawless M; Nguyen M; Paquette D; Turcotte E; Berger A; Mitchell M; Shore GC; Beauparlant P
Mol Cell Biol; 2009 Nov; 29(21):5872-88. PubMed ID: 19703994
[TBL] [Abstract][Full Text] [Related]
57. Anticancer Activities of Novel Nicotinamide Phosphoribosyltransferase Inhibitors in Hematological Malignancies.
Biniecka P; Matsumoto S; Belotti A; Joussot J; Bai JF; Majjigapu SR; Thoueille P; Spaggiari D; Desfontaine V; Piacente F; Bruzzone S; Cea M; Decosterd LA; Vogel P; Nencioni A; Duchosal MA; Nahimana A
Molecules; 2023 Feb; 28(4):. PubMed ID: 36838885
[TBL] [Abstract][Full Text] [Related]
58. Inhibition of nicotinamide phosphoribosyltransferase and depletion of nicotinamide adenine dinucleotide contribute to arsenic trioxide suppression of oral squamous cell carcinoma.
Wang XY; Wang JZ; Gao L; Zhang FY; Wang Q; Liu KJ; Xiang B
Toxicol Appl Pharmacol; 2017 Sep; 331():54-61. PubMed ID: 28501332
[TBL] [Abstract][Full Text] [Related]
59. NAMPT: A potential prognostic and therapeutic biomarker in patients with glioblastoma.
Guo Q; Han N; Shi L; Yang L; Zhang X; Zhou Y; Yu S; Zhang M
Oncol Rep; 2019 Sep; 42(3):963-972. PubMed ID: 31322259
[TBL] [Abstract][Full Text] [Related]
60. Channeling Nicotinamide Phosphoribosyltransferase (NAMPT) to Address Life and Death.
Velma GR; Krider IS; Alves ETM; Courey JM; Laham MS; Thatcher GRJ
J Med Chem; 2024 Apr; 67(8):5999-6026. PubMed ID: 38580317
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]